Cargando…

Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale

BACKGROUND: Chronic heart failure (CHF), which affects >5 million Americans, accounts for >1 million hospitalizations annually. As a part of the Hospital Readmission Reduction Program, the Affordable Care Act requires that the Centers for Medicare and Medicaid Services reduce payments to hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamberlain, Ronald S, Sond, Jaswinder, Mahendraraj, Krishnaraj, Lau, Christine SM, Siracuse, Brianna L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898587/
https://www.ncbi.nlm.nih.gov/pubmed/29670391
http://dx.doi.org/10.2147/IJGM.S150676
_version_ 1783314153420619776
author Chamberlain, Ronald S
Sond, Jaswinder
Mahendraraj, Krishnaraj
Lau, Christine SM
Siracuse, Brianna L
author_facet Chamberlain, Ronald S
Sond, Jaswinder
Mahendraraj, Krishnaraj
Lau, Christine SM
Siracuse, Brianna L
author_sort Chamberlain, Ronald S
collection PubMed
description BACKGROUND: Chronic heart failure (CHF), which affects >5 million Americans, accounts for >1 million hospitalizations annually. As a part of the Hospital Readmission Reduction Program, the Affordable Care Act requires that the Centers for Medicare and Medicaid Services reduce payments to hospitals with excess readmissions. This study sought to develop a scale that reliably predicts readmission rates among patients with CHF. METHODS: The State Inpatient Database (2006–2011) was utilized, and discharge data including demographic and clinical characteristics on 642,448 patients with CHF from California and New York (derivation cohort) and 365,359 patients with CHF from Florida and Washington (validation cohort) were extracted. The Readmission After Heart Failure (RAHF) scale was developed to predict readmission risk. RESULTS: The 30-day readmission rates were 9.42 and 9.17% (derivation and validation cohorts, respectively). Age <65 years, male gender, first income quartile, African American race, race other than African American or Caucasian, Medicare, Medicaid, self-pay/no insurance, drug abuse, renal failure, chronic pulmonary disorder, diabetes, depression, and fluid and electrolyte disorder were associated with higher readmission risk after hospitalization for CHF. The RAHF scale was created and explained the 95% of readmission variability within the validation cohort. The RAHF scale was then used to define the following three levels of risk for readmission: low (RAHF score <12; 7.58% readmission rate), moderate (RAHF score 12–15; 9.78% readmission rate), and high (RAHF score >15; 12.04% readmission rate). The relative risk of readmission was 1.67 for the high-risk group compared with the low-risk group. CONCLUSION: The RAHF scale reliably predicts a patient’s 30-day CHF readmission risk based on demographic and clinical factors present upon initial admission. By risk-stratifying patients, using models such as the RAHF scale, strategies tailored to each patient can be implemented to improve patient outcomes and reduce health care costs.
format Online
Article
Text
id pubmed-5898587
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58985872018-04-18 Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale Chamberlain, Ronald S Sond, Jaswinder Mahendraraj, Krishnaraj Lau, Christine SM Siracuse, Brianna L Int J Gen Med Original Research BACKGROUND: Chronic heart failure (CHF), which affects >5 million Americans, accounts for >1 million hospitalizations annually. As a part of the Hospital Readmission Reduction Program, the Affordable Care Act requires that the Centers for Medicare and Medicaid Services reduce payments to hospitals with excess readmissions. This study sought to develop a scale that reliably predicts readmission rates among patients with CHF. METHODS: The State Inpatient Database (2006–2011) was utilized, and discharge data including demographic and clinical characteristics on 642,448 patients with CHF from California and New York (derivation cohort) and 365,359 patients with CHF from Florida and Washington (validation cohort) were extracted. The Readmission After Heart Failure (RAHF) scale was developed to predict readmission risk. RESULTS: The 30-day readmission rates were 9.42 and 9.17% (derivation and validation cohorts, respectively). Age <65 years, male gender, first income quartile, African American race, race other than African American or Caucasian, Medicare, Medicaid, self-pay/no insurance, drug abuse, renal failure, chronic pulmonary disorder, diabetes, depression, and fluid and electrolyte disorder were associated with higher readmission risk after hospitalization for CHF. The RAHF scale was created and explained the 95% of readmission variability within the validation cohort. The RAHF scale was then used to define the following three levels of risk for readmission: low (RAHF score <12; 7.58% readmission rate), moderate (RAHF score 12–15; 9.78% readmission rate), and high (RAHF score >15; 12.04% readmission rate). The relative risk of readmission was 1.67 for the high-risk group compared with the low-risk group. CONCLUSION: The RAHF scale reliably predicts a patient’s 30-day CHF readmission risk based on demographic and clinical factors present upon initial admission. By risk-stratifying patients, using models such as the RAHF scale, strategies tailored to each patient can be implemented to improve patient outcomes and reduce health care costs. Dove Medical Press 2018-04-09 /pmc/articles/PMC5898587/ /pubmed/29670391 http://dx.doi.org/10.2147/IJGM.S150676 Text en © 2018 Chamberlain et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chamberlain, Ronald S
Sond, Jaswinder
Mahendraraj, Krishnaraj
Lau, Christine SM
Siracuse, Brianna L
Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale
title Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale
title_full Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale
title_fullStr Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale
title_full_unstemmed Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale
title_short Determining 30-day readmission risk for heart failure patients: the Readmission After Heart Failure scale
title_sort determining 30-day readmission risk for heart failure patients: the readmission after heart failure scale
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898587/
https://www.ncbi.nlm.nih.gov/pubmed/29670391
http://dx.doi.org/10.2147/IJGM.S150676
work_keys_str_mv AT chamberlainronalds determining30dayreadmissionriskforheartfailurepatientsthereadmissionafterheartfailurescale
AT sondjaswinder determining30dayreadmissionriskforheartfailurepatientsthereadmissionafterheartfailurescale
AT mahendrarajkrishnaraj determining30dayreadmissionriskforheartfailurepatientsthereadmissionafterheartfailurescale
AT lauchristinesm determining30dayreadmissionriskforheartfailurepatientsthereadmissionafterheartfailurescale
AT siracusebriannal determining30dayreadmissionriskforheartfailurepatientsthereadmissionafterheartfailurescale